Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Moretti

Showing results (221-230 of 223) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 223 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Breast (Edinburgh, Scotland)|July 17, 2017
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyM E Cazzaniga, M Airoldi, V Arcangeli, et al.
Annali Dell'Istituto Superiore Di Sanita|January 1, 1979
[Nutritional research on Toprina (yeasts cultivated on n-paraffins)]R Alimenti, G Antonucci, M P Bernardini, et al.
Pageof 23

Showing results (221-230 of 223) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 223 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Breast (Edinburgh, Scotland)|July 17, 2017
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyM E Cazzaniga, M Airoldi, V Arcangeli, et al.
Annali Dell'Istituto Superiore Di Sanita|January 1, 1979
[Nutritional research on Toprina (yeasts cultivated on n-paraffins)]R Alimenti, G Antonucci, M P Bernardini, et al.
Pageof 23